What counseling should be offered to a pregnant patient at risk of being a carrier for spinal muscular atrophy (SMA)?

Counseling for Pregnant Patients at Risk of Being SMA Carriers

All pregnant women should be offered carrier screening for spinal muscular atrophy (SMA) regardless of ethnicity or family history, with genetic counseling provided both before and after testing. 1

Key Counseling Points

Initial Risk Assessment and Screening Offer

• Universal screening is recommended: The American College of Medical Genetics (ACMG) recommends offering SMA carrier screening to all pregnant patients as part of tier 3 carrier screening, which includes conditions with carrier frequencies ≥1/200 1

• Carrier frequency: The pan-ethnic carrier frequency is approximately 1/54 in the United States, with detection rates of 91.2% 2. Specific ethnic groups show variation:

  • Caucasian: 1/47 (detection rate 94.8%)
  • African American: 1/72 (detection rate 70.5%)
  • Asian populations: approximately 1/50 3

Disease Information to Convey

Explain the severity and inheritance pattern clearly:

• SMA is an autosomal recessive neurodegenerative disorder affecting 1 in 10,000-11,000 live births 2, 4
• It is the leading inherited cause of infant death and second only to cystic fibrosis as a common, life-shortening autosomal recessive disorder 2
• Approximately 94% of cases result from homozygous deletion of the SMN1 gene 3
• The condition causes progressive muscle atrophy, weakness, and in severe forms can be fatal or require permanent ventilation by age 2 without treatment 5

If Patient Tests Positive as a Carrier

Partner testing is essential:

• If the pregnant woman is a carrier (has one SMN1 copy), immediately offer partner testing
• If both partners are carriers, the risk of an affected child is 25% per pregnancy 6
• Explain that current disease-modifying therapies exist (nusinersen, risdiplam, onasemnogene abeparvovec) that have significantly improved outcomes 7, 5

Discuss reproductive options:

• Prenatal diagnostic testing via amniocentesis or chorionic villus sampling if both partners are carriers
• Pregnancy termination options if desired (counseling should be nondirective) 8
• Preimplantation genetic testing for future pregnancies
• Postnatal genetic testing and early treatment initiation if newborn screening is positive

Critical Counseling Nuances

Address the "2+0" carrier scenario:

• Some individuals carry two SMN1 copies on one chromosome (silent carriers) rather than one on each chromosome 6
• Standard carrier tests cannot distinguish between silent carriers (2+0 genotype) and non-carriers (1+1 genotype)
• If a patient has two SMN1 copies but has a family history of SMA, advanced genetic testing with microsatellite marker analysis may be warranted 6
• This distinction is crucial because silent carriers can still have affected children if their partner is a carrier

Emphasize the importance of genetic knowledge:

• Studies show that higher genetic knowledge scores correlate with greater willingness to undergo screening 9
• Provide educational materials (video or written) explaining SMA genetics, inheritance, and screening implications
• Address common misconceptions: lack of family history does NOT eliminate carrier risk 9

Family Planning Considerations

For current pregnancy:

• Timing is critical—offer screening early in pregnancy to allow time for partner testing and informed decision-making
• If both partners are carriers, expedite prenatal diagnostic testing to preserve reproductive options 8

For future pregnancies:

• Discuss that carrier status is lifelong and relevant for all future pregnancies
• Extended family members (siblings, cousins) have up to 50% chance of being carriers and should be informed 6
• Preconception genetic counseling is ideal for subsequent pregnancies

Practical Implementation

Pre-test counseling should include:

• Explanation that screening helps make informed reproductive decisions and avoid having a child with SMA 9
• Discussion of what positive and negative results mean
• Clarification that a negative result reduces but does not eliminate risk (detection rate is 91.2%, not 100%) 2

Post-test counseling should address:

• If negative: Residual risk remains approximately 1/1,000 for having an affected child
• If positive: Immediate need for partner testing and discussion of next steps
• Emotional support and connection to genetic counseling resources

Common Pitfalls to Avoid

• Do not assume family history is required to justify screening—SMA screening should be universal 1
• Do not delay partner testing if the patient is a carrier—time is critical for decision-making
• Do not overlook the possibility of de novo deletions, which can complicate risk assessment in families with two-copy carriers 6
• Do not forget to document and communicate results clearly to ensure continuity of care across pregnancies